Innovating Patient-Centric, Longer-Lasting Delivery to Specific Ocular Targets to Strengthen Adherence to Transformative Ophthalmic Therapies with Enhanced Durability & Formulation
As the global burden of retinal and ocular diseases continues to rise, the race to develop safer, longer-lasting, and less invasive treatments is accelerating, and at the heart of that challenge lies drug delivery. The 4th Ophthalmic Drug Delivery Summit arrived at a pivotal moment, brought together 80+ leading experts from pharma and biotech to tackle the toughest delivery hurdles limiting the impact of cutting-edge therapeutics.
With industry momentum building around sustained-release technologies, suprachoroidal administration, and innovative device-drug combinations, this summit was your gateway to the breakthroughs redefining ocular treatment. From translating long-acting formulations into clinical success to navigating regulatory complexities early, this was the only event dedicated to transforming how and where ophthalmic therapies work - making it a must-attend for anyone shaping the future of eye care.
I truly enjoyed the intimate nature of the conference. It allowed for great networking with people at the top of the field as well as those just entering it.
Chemistry, Manufacturing & Controls Program Management Manager, Regeneron Pharmaceuticals
Excellent line-up of industry experts. Very engaging and innovative content.
Senior Manager, R&D Engineering Team Leader, Teva Pharmaceuticals
The people attending the meeting were the world experts on the topic.
Co-Founder & Chief Innovation Officer, Aviceda Therapeutics
2026 Speakers
Attending Companies Included
Explore Related Events
Explore the Agenda
Discover the latest innovations transforming ocular drug delivery, from long-acting implants to suprachoroidal access.
Partner With Us
Connect with top-tier drug developers actively seeking expert collaborators across formulation, devices, imaging, and more.
Join Other Ocular Delivery Experts
Register now and look forward to networking with 80+ leading scientists and innovators advancing the future of ophthalmic therapeutics.